Carisma Therapeutics Inc. has confirmed that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for their novel product, CT-0525.

Bio-Thera Solutions has reported encouraging outcomes from its pivotal Phase 3 clinical trial involving BAT2206, a candidate biosimilar for Stelara®.

Halia Therapeutics Reveals Promising Initial Clinical Outcomes for Drug HT-6184 during the Fifth Summit on Inflammasome Treatment Strategies.

OncoResponse, a clinical-stage biotech innovator specializing in immunotherapy derived from elite cancer survivors, announced the first dosing in a Phase 1/2 trial of OR502.

Opsidio has initiated dosing of the initial participant in a Phase 2a study evaluating OpSCF for the treatment of moderate to severe eczema.

ASC Therapeutics has reported the inaugural administration to a patient in their Phase I/IIa study for their prime drug, ASC618, conducted at Arkansas Children's Hospital.

Longboard Pharmaceuticals, Inc., a company focused on developing new treatments for neurological conditions, has announced the start of a Phase 1 trial. This randomized, double-blind, placebo-controlled study will assess their drug candidate, LP659, in a Single Ascending Dose (SAD) format.

OliX Pharmaceuticals has disclosed encouraging initial safety outcomes and signs of effectiveness from a Phase 1 study evaluating OLX10212 for treating age-related macular degeneration.

Arrowhead Pharmaceuticals has submitted an application to begin an early-stage clinical trial, evaluating ARO-DM1 in patients with Myotonic Dystrophy Type 1.

Internationally recognized biotech company CSL, in partnership with Arcturus Therapeutics, has made public that the Ministry of Health, Labor and Welfare in Japan has officially sanctioned the use of ARCT-154.

Rallybio Reveals Initial Multi-Dose Results from Finalized Phase 1 Evaluation on Safety and Drug Dynamics for RLYB212, a Monoclonal Antibody Targeting HPA-1a to Avert Thrombocytopenia in Infants and Newborns.

Tectonic Therapeutics, known for GPCR-targeted therapies, has successfully dosed the first cohort in human trials for its Fc-relaxin RXFP1 receptor project.